First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

@article{Wuyts2016FirstDO,
  title={First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value},
  author={W. Wuyts and M. Kolb and S. Stowasser and W. Stansen and J. T. Huggins and G. Raghu},
  journal={Lung},
  year={2016},
  volume={194},
  pages={739 - 743}
}
  • W. Wuyts, M. Kolb, +3 authors G. Raghu
  • Published 2016
  • Medicine
  • Lung
  • In the Phase III INPULSIS® trials, 52 weeks’ treatment with nintedanib reduced decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Patients who completed the INPULSIS® trials could receive nintedanib in an open-label extension trial (INPULSIS®-ON). Patients with FVC <50 % predicted were excluded from INPULSIS®, but could participate in INPULSIS®-ON. In patients with baseline FVC ≤50 % and >50 % predicted at the start of INPULSIS®-ON, the… CONTINUE READING

    Tables and Topics from this paper.

    Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
    • 30
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 25 REFERENCES